Close Menu
Invitrogen continued to cash in on changes instituted through 2006 into early this year as it reported a $40 million profit this week for the third quarter, compared to a loss of $129.8 million a year ago.
Revenues for the three months ended Sept. 30 rose 10.8 percent to $315 million from $284.2 million a year ago. Revenues for the company’s BioDiscovery division, which houses Invitrogen’s proteomics tools, climbed 10.5 percent to $220.4 million from $199.5 million one year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.